The biggest regulatory event in telehealth this year happened quietly in February. Novo Nordisk sued Hims & Hers for patent infringement over compounded semaglutide. The FDA followed with an enforcement statement. And the entire compounded GLP-1 industry — which had been growing at a breakneck pace since 2022 — started navigating a fundamentally different legal landscape.

Here is what actually changed and what it means if you are currently on a compounded GLP-1 program.

The background: why compounded semaglutide became legal in the first place

When the FDA designated semaglutide as being in shortage (which happened in 2022), federal compounding law allowed licensed 503A and 503B pharmacies to produce compounded versions. This created the entire telehealth compounded GLP-1 market — platforms like Hims, Ro, Henry Meds, DirectMeds, and dozens of others were all operating legally under the shortage exemption.

The FDA declared the semaglutide shortage resolved in February 2025. That created the first tightening. 503B outsourcing facilities (which do large-scale production) lost their shortage exemption at that point. 503A pharmacies retained some latitude for patient-specific compounding.

What happened in early 2026

On February 5, 2026, Hims & Hers launched compounded semaglutide tablets commercially — the same day TrumpRx launched, advertising FDA-approved GLP-1 options at $149–299/month. Whether that was coincidence or coordination is unclear, but the timing triggered the crackdown.

Novo Nordisk sued Hims & Hers on February 9, alleging patent infringement and the use of "inauthentic API" — specifically semaglutide in salt forms (sodium or acetate) rather than the base form used in approved products.

The FDA issued an enforcement statement on February 6, clarifying that it intends to prioritize action against mass-marketed compounded GLP-1 products that do not qualify as patient-specific.

What this means for patients currently on compounded programs

Most 503A telehealth platforms — including the majority on ClinicLayer — are continuing to operate. Patient-specific compounding pursuant to a physician order, based on individual clinical need, remains legally defensible under 503A of the FD&C Act.

What changed: mass-produced compounded product marketed broadly to any eligible patient is on much shakier ground than it was in 2023 or 2024.

The practical bottom line

If you are currently receiving compounded semaglutide from a reputable 503A pharmacy via a licensed telehealth provider, the risk of your program abruptly stopping is lower than the headlines suggest. But longer-term availability is genuinely less certain than it was two years ago.

What you should do: verify that your clinic uses a 503A (not 503B) pharmacy, confirm they are prescribing based on your individual clinical profile, and ask whether they use base-form semaglutide rather than salt forms. All of the programs on ClinicLayer that we have confirmed use 503A pharmacies.

What this means for pricing

Enforcement pressure typically pushes prices up, not down. If major compounders exit the market or reduce volume, the remaining players face less competition. Watch for pricing changes over the next 6–12 months.